What ARS Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 5 |
| Total trades | 0 | 10 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 76,828 |
| Disposed | 0 | 566,563 |
| Net activity | +0 | −489,735 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Karas Eric | Chief Commercial Officer | Jun 12 | Open-market sale · S | −25,000 | $10.00 | −$250K | 12,176 |
| Karas Eric | Chief Commercial Officer | Jun 12 | Exercise / conversion · M | +25,000 | $1.50 | +$37.5K | 37,176 |
| Fitzpatrick Alexander A | Chief Legal Officer | Jun 12 | Open-market sale · S | −3,355 | $10.00 | −$33.6K | 90,910 |
| Dorsey Brian | Chief Operating Officer | Nov 13 | Open-market sale · S | −21,828 | $8.71 | −$190K | 10,789 |
| Dorsey Brian | Chief Operating Officer | Nov 13 | Exercise / conversion · M | +21,828 | $0.64 | +$14K | 32,617 |
| Shah Pratik | Director | Nov 12 | Gift · G | −100,000 | — | — | 4,474,554 |
| Shah Pratik | Director | Nov 12 | Gift · G | −250,000 | — | — | 4,574,554 |
| Chakma Justin | Chief Business Officer | Nov 12 | Open-market sale · S | −136,380 | $8.86 | −$1.21M | 0 |
| Chakma Justin | Chief Business Officer | Nov 12 | Open-market sale · S | −30,000 | $8.91 | −$267K | 136,380 |
| Chakma Justin | Chief Business Officer | Nov 12 | Exercise / conversion · M | +30,000 | $0.84 | +$25.2K | 166,380 |
| Scott Kathleen D. | Chief Financial Officer | Aug 21 | Disclosed 10b5-1 sale · S | −12,500 | $15.00 | −$188K | 10,042 |
| Scott Kathleen D. | Chief Financial Officer | Aug 21 | Exercise / conversion · M | +12,500 | $1.50 | +$18.8K | 22,542 |
| Lowenthal Richard E | PRESIDENT AND CEO | Aug 21 | Disclosed 10b5-1 sale · S | −50,000 | $14.49 | −$724K | 1,196,494 |
| Tanimoto Sarina | CHIEF MEDICAL OFFICER | Aug 20 | Disclosed 10b5-1 sale · S | −37,656 | $14.09 | −$531K | 1,247,447 |
| Tanimoto Sarina | CHIEF MEDICAL OFFICER | Aug 19 | Disclosed 10b5-1 sale · S | −12,344 | $14.03 | −$173K | 1,285,103 |
| Karas Eric | Chief Commercial Officer | Jul 01 | Open-market sale · S | −15,000 | $16.99 | −$255K | 10,315 |
| Karas Eric | Chief Commercial Officer | Jul 01 | Exercise / conversion · M | +15,000 | $1.50 | +$22.5K | 25,315 |
| Flynn James E | 10% owner | Jun 27 | Open-market sale · S | −370,074 | $18.46 | −$6.83M | 4,887,254 |
| Flynn James E | 10% owner | Jun 27 | Open-market sale · S | −370,075 | $18.46 | −$6.83M | 4,887,254 |
| Karas Eric | Chief Commercial Officer | Jun 18 | Open-market sale · S | −15,000 | $16.00 | −$240K | 7,696 |
Loading...
